DOCSLIB.ORG

Dibutyl Sebacate) Final Designation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dibutyl Sebacate) Final Designation Supporting Information for Low-Priority Substance Decanedioic Acid, 1,10-Dibutyl Ester (CASRN 109-43-3) (Dibutyl Sebacate) Final Designation February 20, 2020 Office of Pollution Prevention and Toxics U.S. Environmental Protection Agency 1200 Pennsylvania Avenue Washington, DC 20460 Contents 1. Introduction ................................................................................................................................................................ 1 2. Background on Dibutyl Sebacate ............................................................................................................................. 3 3. Physical-Chemical Properties ................................................................................................................................... 4 3.1 References ...................................................................................................................................................... 6 4. Relevant Assessment History ................................................................................................................................... 7 5. Conditions of Use ....................................................................................................................................................... 8 6. Hazard Characterization .......................................................................................................................................... 13 6.1 Human Health Hazard ................................................................................................................................... 16 6.1.1 Absorption, Distribution, Metabolism, and Excretion .................................................................... 17 6.1.2 Acute Toxicity ................................................................................................................................ 18 6.1.3 Repeated Dose Toxicity ................................................................................................................ 18 6.1.4 Reproductive and Developmental Toxicity.................................................................................... 18 6.1.5 Genotoxicity .................................................................................................................................. 19 6.1.6 Carcinogenicity ............................................................................................................................. 19 6.1.7 Neurotoxicity ................................................................................................................................. 19 6.1.8 Skin Sensitization .......................................................................................................................... 20 6.1.9 Respiratory Sensitization .............................................................................................................. 20 6.1.10 Immunotoxicity .............................................................................................................................. 20 6.1.11 Skin Irritation ................................................................................................................................. 21 6.1.12 Eye Irritation ................................................................................................................................. 21 6.1.13 Hazards to Potentially Exposed or Susceptible Subpopulations ................................................. 21 6.2 Environmental Hazard ................................................................................................................................... 22 6.2.1 Acute Aquatic Toxicity ................................................................................................................... 22 6.2.2 Chronic Aquatic Toxicity ............................................................................................................... 22 6.2.3 Terrestrial Toxicity ......................................................................................................................... 23 6.3 Persistence and Bioaccumulation Potential ................................................................................................... 23 i 6.3.1 Persistence ................................................................................................................................... 23 6.3.2 Bioaccumulation Potential ............................................................................................................. 24 7. Exposure Characterization ...................................................................................................................................... 25 7.1 Production Volume Information ..................................................................................................................... 25 7.2 Exposures to the Environment ....................................................................................................................... 25 7.3 Exposures to the General Population ............................................................................................................ 26 7.4 Exposures to Potentially Exposed or Susceptible Subpopulations ................................................................ 26 7.4.1 Exposures to Workers ................................................................................................................... 26 7.4.3 Exposures to Consumers .............................................................................................................. 27 7.4.2 Exposures to Children ................................................................................................................... 27 8. Summary of Findings ....................................................................................................................................................... 28 8.1. Hazard and Exposure Potential of the Chemical Substance ......................................................................... 28 8.2. Persistence and Bioaccumulation .................................................................................................................. 29 8.3. Potentially Exposed or Susceptible Subpopulations ...................................................................................... 29 8.4. Storage near Significant Sources of Drinking Water ..................................................................................... 30 8.5. Conditions of Use or Significant Changes in Conditions of Use of the Chemical Substance ........................ 31 8.6. The Volume or Significant Changes in Volume of the Chemical Substance Manufactured or Processed .... 32 8.7. Other Considerations ..................................................................................................................................... 32 9. Final Designation .............................................................................................................................................................. 33 Appendix A: Conditions of Use Characterization ................................................................................................................. I A.1. CDR Manufacturers and Production Volume .................................................................................................... I A.2. Uses ................................................................................................................................................................. II A.2.1 Methods for Uses Products Table ................................................................................................... II A.2.2 Uses of Dibutyl Sebacate ............................................................................................................... IV A.3 References ............................................................................................................................................... XXVII Appendix B: Hazard Characterization ............................................................................................................................. XXIX B.1 References ............................................................................................................................................. XXXVII Appendix C: Literature Search Outcomes .................................................................................................................... XXXIX C.1 Literature Search and Review ................................................................................................................. XXXIX C.1.1 Search for Analog Data ................................................................................................................. XL C.1.2 Search Terms and Results ........................................................................................................... XL ii C.2 Excluded Studies and Rationale .................................................................................................................. XLII C.2.1 Human Health Hazard Excluded References ............................................................................. XLII C.2.2 Environmental Hazard ............................................................................................................ XLVIII C.2.3 Fate................................................................................................................................................. L iii Tables Table
Load more

Recommended publications
  • Altered Metabolome of Lipids and Amino Acids Species: a Source of Early Signature Biomarkers of T2DM
    Journal of Clinical Medicine Review Altered Metabolome of Lipids and Amino Acids Species: A Source of Early Signature Biomarkers of T2DM Ahsan Hameed 1 , Patrycja Mojsak 1, Angelika Buczynska 2 , Hafiz Ansar Rasul Suleria 3 , Adam Kretowski 1,2 and Michal Ciborowski 1,* 1 Clinical Research Center, Medical University of Bialystok, Jana Kili´nskiegoStreet 1, 15-089 Bialystok, Poland; [email protected] (A.H.); [email protected] (P.M.); [email protected] (A.K.) 2 Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, 15-089 Bialystok, Poland; [email protected] 3 School of Agriculture and Food System, The University of Melbourne, Parkville, VIC 3010, Australia; hafi[email protected] * Correspondence: [email protected] Received: 27 June 2020; Accepted: 14 July 2020; Published: 16 July 2020 Abstract: Diabetes mellitus, a disease of modern civilization, is considered the major mainstay of mortalities around the globe. A great number of biochemical changes have been proposed to occur at metabolic levels between perturbed glucose, amino acid, and lipid metabolism to finally diagnoe diabetes mellitus. This window period, which varies from person to person, provides us with a unique opportunity for early detection, delaying, deferral and even prevention of diabetes. The early detection of hyperglycemia and dyslipidemia is based upon the detection and identification of biomarkers originating from perturbed glucose, amino acid, and lipid metabolism. The emerging “OMICS” technologies, such as metabolomics coupled with statistical and bioinformatics tools, proved to be quite useful to study changes in physiological and biochemical processes at the metabolic level prior to an eventual diagnosis of DM.
    [Show full text]
  • Dibasic Acids for Nylon Manufacture
    - e Report No. 75 DIBASIC ACIDS FOR NYLON MANUFACTURE by YEN-CHEN YEN October 1971 A private report by the PROCESS ECONOMICS PROGRAM STANFORD RESEARCH INSTITUTE MENLO PARK, CALIFORNIA CONTENTS INTRODUCTION, ....................... 1 SUMMARY .......................... 3 General Aspects ...................... 3 Technical Aspects ..................... 7 INDUSTRY STATUS ...................... 15 Applications and Consumption of Sebacic Acid ........ 15 Applications and Consumption of Azelaic Acid ........ 16 Applications of Dodecanedioic and Suberic Acids ...... 16 Applications of Cyclododecatriene and Cyclooctadiene .... 17 Producers ......................... 17 Prices ........................... 18 DIBASIC ACIDS FOR MANUFACTURE OF POLYAMIDES ........ 21 CYCLOOLIGOMERIZATIONOF BUTADIENE ............. 29 Chemistry ......................... 29 Ziegler Catalyst ..................... 30 Nickel Catalyst ..................... 33 Other Catalysts ..................... 34 Co-Cyclooligomerization ................. 34 Mechanism ........................ 35 By-products and Impurities ................ 37 Review of Processes .................... 38 A Process for Manufacture of Cyclododecatriene ....... 54 Process Description ................... 54 Process Discussion .................... 60 Cost Estimates ...................... 60 A Process for Manufacture of Cyclooctadiene ........ 65 Process Description ................... 65 Process Discussion .................... 70 Cost Estimates ...................... 70 A Process for Manufacture of Cyclodecadiene
    [Show full text]
  • Microwave-Assisted Low-Temperature Dehydration Polycondensation of Dicarboxylic Acids and Diols
    Polymer Journal (2011) 43, 1003–1007 & The Society of Polymer Science, Japan (SPSJ) All rights reserved 0032-3896/11 $32.00 www.nature.com/pj RAPID COMMUNICATION Microwave-assisted low-temperature dehydration polycondensation of dicarboxylic acids and diols Polymer Journal (2011) 43, 1003–1007; doi:10.1038/pj.2011.107; published online 26 October 2011 INTRODUCTION time (4100 h). Therefore, we next focused on has been no report concerning a Currently, because of increasing concerns identifying more active catalysts and found that non-thermal effect in microwave-assisted about damage to the environment, the devel- scandium and thulium bis(nonafluorobutane- polycondensation reactions,33,34 although opment of new, eco-friendly (industrially sulfonyl)imide ((Sc(NNf2)3) and (Tm(NNf2)3)) there has been a report that non-thermal relevant) chemical reactions and materials is were more efficient catalysts and allowed us microwaves have a role in the chain polymer- crucial. Aliphatic polyesters have attracted to obtain high-molecular-weight polyesters ization of a lactone.32 Therefore, we studied 4 much interest as environmentally benign, (Mn42.0Â10 ) from adipic acid (AdA) and microwave-assisted syntheses of polyesters at biodegradable polymers.1,2 In general, alipha- 3-methyl-1,5-pentanediol (MPD) at 60 1Cina a relatively low temperature (80 1C) using a tic polyesters are commercially produced by shortperiodoftime(24h)andwithasmaller microwave chamber equipped with a tem- polycondensation of a dicarboxylic acid and a amount of catalyst (0.1 mol%) than had pre- perature control, and the results are reported 1.1–1.5 mol excess of a diol at a temperature viously been possible.26 herein.
    [Show full text]
  • 1. PUBLIC HEALTH STATEMENT This Statement Was Prepared to Give
    OTTO FUEL II AND ITS COMPONENTS 1 1. PUBLIC HEALTH STATEMENT This statement was prepared to give you information about Otto Fuel II and its components, and to emphasize the human health effects that may result from exposure to them. The Environmental Protection Agency (EPA) has identified 1,397 hazardous waste sites as the most serious in the nation. These sites make up the National Priorities List (NPL) and are the sites targeted for long-term federal clean-up activities. Otto Fuel II has been found at two of the sites on the NPL. However, the number of NPL sites evaluated for Otto Fuel II and its components is not known. As EPA evaluates more sites, the number of sites at which Otto Fuel II and its components are found may increase. This information is important for you to know because Otto Fuel II and its components may cause harmful health effects and because these sites are potential or actual sources of human exposure to Otto Fuel II and its components. When a chemical is released from a large area, such as an industrial plant, or from a container, such as a drum or bottle, it enters the environment as a chemical emission. This emission, which is also called a release, does not always lead to exposure. You can be exposed to a chemical only when you come into contact with the chemical. You may be exposed to it in the environment by breathing, eating or drinking substances containing the chemical, or from skin contact with it. If you are exposed to a hazardous chemical such as Otto Fuel II and its components, several factors will determine whether harmful health effects will occur, and what the type and severity of those health effects will be.
    [Show full text]
  • Pharmacokinetics of Sebacic Acid in Rats
    European Review for Medical and Pharmacological Sciences 1999; 3: 119-125 Pharmacokinetics of sebacic acid in rats A.M.R. FAVUZZI, G. MINGRONE, A. BERTUZZI*, S. SALINARI**, A. GANDOLFI*, A.V. GRECO Istituto di Medicina Interna e Geriatria, Catholic University - Rome (Italy) *Istituto di Analisi dei Sistemi ed Informatica, CNR - Rome (Italy) **Dipartimento di Informatica e Sistemistica, Facoltà di Ingegneria, “La Sapienza” University - Rome (Italy) Abstract. – The pharmacokinetics of disodi- enteral nutrition (TPN) as an alternate ener- um sebacate (Sb) was studied in Wistar rats of gy source1-3. The advantage of these diacids both sexes. Sebacate was administered either as over conventional lipid substrates (both long intra-peritoneal (i.p.) bolus (six doses ranging from 10 mg to 320 mg) or as oral bolus (two doses: 80 and medium chain triglycerides) is related to and 160 mg). Plasma and urinary concentrations the immediate availability of their com- of Sb and urinary concentrations of Sb and its pounds. The salts of dicarboxylic acids are products of β-oxidation (suberic and adipic acids) highly water soluble and thus can be directly were measured by an improved method using administered through a peripheral venous gas-liquid chromatography/mass-spectrometry. route. Unlike long chain triglycerides (LCT), A single compartment with two linear elimi- or medium chain triglycerides (MCT), which nation routes was selected after no increase in significance was shown by an additional com- are available under emulsion form for clinical partment and after a saturable mechanism was use, they do not require complex and expen- found to be unsuitable. Both renal and non-re- sive production procedures.
    [Show full text]
  • D 2.1 Background Information and Biorefinery Status, Potential and Sustainability
    Project no.: 241535 – FP7 Project acronym: Star-COLIBRI Project title: Strategic Targets for 2020 – Collaboration Initiative on Biorefineries Instrument: Specific Support Action Thematic Priority: Coordination and support actions D 2.1 Background information and biorefinery status, potential and Sustainability – Task 2.1.2 Market and Consumers; Carbohydrates – Due date of deliverable: March 31, 2010 Start date of project: 01.11.2009 Duration: 24 months Organisation name of lead contractor for this deliverable: UoY Version: 1.0 Project co-funded by the European Commission within the Seventh Framework Programme (2007-2011) Dissemination level PU Public X PP Restricted to other programme participants (including the Commission Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) Star-COLIBRI - Deliverable 2.1 D 2.1 Background information and biorefinery status, potential and Sustainability – Task 2.1.2 Market and Consumers; Carbohydrates – H.L. Bos, P.F.H. Harmsen & E. Annevelink Wageningen UR – Food & Biobased Research Version 18/03/10 Task 2.1.2 Market and Consumers; Carbohydrates 2 Star-COLIBRI - Deliverable 2.1 Content Management summary ............................................................................................................... 4 1 Introduction ........................................................................................................................ 5 1.1 Task description
    [Show full text]
  • United States Patent Office Patented
    2,826,604 United States Patent Office Patented. Mar. 11, 1958 2 (130-140 C.), the decalyl acetate being recoverable from the reaction mixture by distillation of the neutralized re 2,826,604 action liquid. The recovered product was a straw-colored PREPARATION OF DECAHYDRONAPHTHYL fragrant oil, which was established to be 1-decallyl acetate. ACETATE 5 The position of the acetoxy group was determined by William E. Erner, Wilmington, Del, assignor to Houdry hydrolysis of the ester to the alcohol and subsequent Process Corporation, Wilmington, Del, a corporation conversion to decalone-1 by chromic acid-acetic acid oxi of Delaware dation. - The aceto-oxidation of Decalin can be carried out No Drawing. Application June 2, 1955 10 in the presence of oxidation catalysts of the type em Serial No. 512,853 bodied in the metal salts of the lower fatty acids. Cobalt 2 Claims. (C. 260-488) acetate proved outstanding among the metallic-soap oxi dation catalysts studied. The use of benzoyl peroxide at the start of the process has been found advantageous The present invention relates to the preparation of 1 5 in decreasing the induction period and in giving uni decahydronaphthyl alcohols and the corresponding acetic formly high yields. acid ester and ketone derivatives of Said alcohols. The ratios of Decalin - to acetic anhydride in the oper More particularly the invention is concerned with the ation of the process are not critical, but practical con production of saturated polynuclear carbocyclic com siderations favor the use of at least one-half mol of pounds of the type 20 acetic anhydride per mol of Decalin.
    [Show full text]
  • Chemo-Enzymatic Cascades to Produce Cycloalkenes from Bio-Based Resources
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by edoc ARTICLE https://doi.org/10.1038/s41467-019-13071-y OPEN Chemo-enzymatic cascades to produce cycloalkenes from bio-based resources Shuke Wu 1,3*, Yi Zhou 1, Daniel Gerngross 2, Markus Jeschek 2 & Thomas R. Ward 1* Engineered enzyme cascades offer powerful tools to convert renewable resources into value- added products. Man-made catalysts give access to new-to-nature reactivities that may complement the enzyme’s repertoire. Their mutual incompatibility, however, challenges their 1234567890():,; integration into concurrent chemo-enzymatic cascades. Herein we show that compartmen- talization of complex enzyme cascades within E. coli whole cells enables the simultaneous use of a metathesis catalyst, thus allowing the sustainable one-pot production of cycloalkenes from oleic acid. Cycloheptene is produced from oleic acid via a concurrent enzymatic oxi- dative decarboxylation and ring-closing metathesis. Cyclohexene and cyclopentene are produced from oleic acid via either a six- or eight-step enzyme cascade involving hydration, oxidation, hydrolysis and decarboxylation, followed by ring-closing metathesis. Integration of an upstream hydrolase enables the usage of olive oil as the substrate for the production of cycloalkenes. This work highlights the potential of integrating organometallic catalysis with whole-cell enzyme cascades of high complexity to enable sustainable chemistry. 1 Department of Chemistry, University of Basel, Mattenstrasse 24a, BPR 1096, CH-4058 Basel, Switzerland. 2 Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, CH-4058 Basel, Switzerland. 3Present address: Institute of Biochemistry, University of Greifswald, Felix- Hausdorff-Str.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,406,708 B1 Kairnerud Et Al
    USOO6406708B1 (12) United States Patent (10) Patent No.: US 6,406,708 B1 Kairnerud et al. (45) Date of Patent: Jun. 18, 2002 (54) THERAPEUTIC COMPOSITIONS WO WO 96/11572 A1 4/1996 WO WO 96/21422 A1 7/1996 (75) Inventors: Lars Kärnerud, Tenhult; Stellan WO WO 98/22083 A1 5/1998 Olmeskog, Aneby, both of (SE) OTHER PUBLICATIONS (73) Assignee: Interhealth AB, Huskvarna (SE) Patent Abstracts of Japan, “JP 61-227517 A, Lion Corp., published Oct. 9, 1986”, vol. 11, No. 69 C-407. (*) Notice: Subject to any disclaimer, the term of this Patent Abstracts of Japan “10-087458 A., Lion Corp., pub patent is extended or adjusted under 35 lished Apr. 7, 1998”. U.S.C. 154(b) by 0 days. Patent Abstracts of Japan, “JP 07-138125A,” Shiseido Co. Ltd., published May 30, 1995, vol. 95, No. 5. (21) Appl. No.: 09/700,215 Hoffmann SL et al., “Safety, Immunogenicity, And Efficacy (22) PCT Filed: May 12, 1999 Of A Malaria Sporozoite Vaccine Administered With Mono phosphoryl Lipid A, Cell Wall Skeleton Of Mycobacteria, (86) PCT No.: PCT/SE99/00819 And Squalane AS Adjuvent” Am J Trop Med Hyg, 51(5), pp. S371 (c)(1), 603–612, Nov. 1994. Abstract. (2), (4) Date: Nov. 13, 2000 Allison AC, “Adjuvants and Immune Enhancement' Int. J. Technol. Assess Health Care, 10(1), pp., 107-120, Winter (87) PCT Pub. No.: WO99/58104 1994. Abstract. Stone HD et al., “Efficacy of Experimental Newcastle Dis PCT Pub. Date: Nov. 18, 1999 ease Water-In-Oil Oil-Emulsion Vaccines Formulated from (30) Foreign Application Priority Data Squalane and Squalane.
    [Show full text]
  • Effect of Oral Sebacic Acid on Postprandial Glycemia, Insulinemia, and Glucose Rate of Appearance in Type 2 Diabetes
    Clinical Care/Education/Nutrition/Psychosocial Research ORIGINAL ARTICLE Effect of Oral Sebacic Acid on Postprandial Glycemia, Insulinemia, and Glucose Rate of Appearance in Type 2 Diabetes 1 1 AMERIGO IACONELLI, MD ANGELA FAVUZZI, MD beneficial in terms of reduction of circu- 2 3 AMALIA GASTALDELLI, PHD CHRISTOPHE BINNERT, PHD lating levels of glucose, insulin, and free 1 3 CHIARA CHIELLINI, PHD KATHERINE MACE´, PHD 1 1 fatty acids in type 2 diabetes. Thus, the DONATELLA GNIULI, MD GELTRUDE MINGRONE, MD, PHD availability of snacks poor in fat and that do not induce hyperglycemia and/or overstimulate insulin secretion would be OBJECTIVE — Dicarboxylic acids are natural products with the potential of being an alter- a good tool in the diet of insulin-resistant, nate dietary source of energy. We aimed to evaluate the effect of sebacic acid (a 10-carbon type 2 diabetic subjects. dicarboxylic acid; C10) ingestion on postprandial glycemia and glucose rate of appearance (Ra) in healthy and type 2 diabetic subjects. Furthermore, the effect of C10 on insulin-mediated Dicarboxylic acids are naturally oc- glucose uptake and on GLUT4 expression was assessed in L6 muscle cells in vitro. curring substances produced by both higher plants and animals via ␻-oxidation RESEARCH DESIGN AND METHODS — Subjects ingested a mixed meal (50% car- of fatty acids (6,7). In plants, long-chain bohydrates, 15% proteins, and 35% lipids) containing 0 g (control) or 10 g C10 in addition to dicarboxylic acids are components of nat- the meal or 23 g C10 as a substitute of fats. ural protective polymers, cutin and RESULTS — In type 2 diabetic subjects, the incremental glucose area under the curve (AUC) suberin, which support biopolyesters in- decreased by 42% (P Ͻ 0.05) and 70% (P Ͻ 0.05) in the 10 g C10 and 23 g C10 groups, volved in waterproofing the leaves and respectively.
    [Show full text]
  • Acetyl Tributyl Citrate | C20H34O8 - Pubchem
    12/31/2020 Acetyl tributyl citrate | C20H34O8 - PubChem COVID-19 is an emerging, rapidly evolving situation. Get the latest public health information from CDC: https://www.coronavirus.gov. Get the latest research from NIH: https://www.nih.gov/coronavirus. COMPOUND SUMMARY Acetyl tributyl citrate PubChem CID 6505 Structure 2D Find Similar Structures Chemical Safety Laboratory Chemical Safety Summary (LCSS) Datasheet Molecular Formula C20H34O8 ACETYL TRIBUTYL CITRATE 77-90-7 tributyl 2-acetoxypropane-1,2,3-tricarboxylate Synonyms Tributyl O-acetylcitrate Acetyltributyl citrate More... Molecular Weight 402.5 g/mol Modify Create Dates 2020-12-26 2005-03-26 https://pubchem.ncbi.nlm.nih.gov/compound/6505 1/46 12/31/2020 Acetyl tributyl citrate | C20H34O8 - PubChem 1 Structures 1.1 2D Structure Chemical Structure Depiction PubChem 1.2 3D Status Conformer generation is disallowed since too flexible PubChem https://pubchem.ncbi.nlm.nih.gov/compound/6505 2/46 12/31/2020 Acetyl tributyl citrate | C20H34O8 - PubChem 2 Names and Identifiers 2.1 Computed Descriptors 2.1.1 IUPAC Name tributyl 2-acetyloxypropane-1,2,3-tricarboxylate Computed by LexiChem 2.6.6 (PubChem release 2019.06.18) PubChem 2.1.2 InChI InChI=1S/C20H34O8/c1-5-8-11-25-17(22)14-20(28-16(4)21,19(24)27-13-10-7-3)15-18(23)26-12-9-6-2/h5-15H2,1-4H3 Computed by InChI 1.0.5 (PubChem release 2019.06.18) PubChem 2.1.3 InChI Key QZCLKYGREBVARF-UHFFFAOYSA-N Computed by InChI 1.0.5 (PubChem release 2019.06.18) PubChem 2.1.4 Canonical SMILES CCCCOC(=O)CC(CC(=O)OCCCC)(C(=O)OCCCC)OC(=O)C Computed
    [Show full text]
  • Dissociation Constants of Organic Acids and Bases
    DISSOCIATION CONSTANTS OF ORGANIC ACIDS AND BASES This table lists the dissociation (ionization) constants of over pKa + pKb = pKwater = 14.00 (at 25°C) 1070 organic acids, bases, and amphoteric compounds. All data apply to dilute aqueous solutions and are presented as values of Compounds are listed by molecular formula in Hill order. pKa, which is defined as the negative of the logarithm of the equi- librium constant K for the reaction a References HA H+ + A- 1. Perrin, D. D., Dissociation Constants of Organic Bases in Aqueous i.e., Solution, Butterworths, London, 1965; Supplement, 1972. 2. Serjeant, E. P., and Dempsey, B., Ionization Constants of Organic Acids + - Ka = [H ][A ]/[HA] in Aqueous Solution, Pergamon, Oxford, 1979. 3. Albert, A., “Ionization Constants of Heterocyclic Substances”, in where [H+], etc. represent the concentrations of the respective Katritzky, A. R., Ed., Physical Methods in Heterocyclic Chemistry, - species in mol/L. It follows that pKa = pH + log[HA] – log[A ], so Academic Press, New York, 1963. 4. Sober, H.A., Ed., CRC Handbook of Biochemistry, CRC Press, Boca that a solution with 50% dissociation has pH equal to the pKa of the acid. Raton, FL, 1968. 5. Perrin, D. D., Dempsey, B., and Serjeant, E. P., pK Prediction for Data for bases are presented as pK values for the conjugate acid, a a Organic Acids and Bases, Chapman and Hall, London, 1981. i.e., for the reaction 6. Albert, A., and Serjeant, E. P., The Determination of Ionization + + Constants, Third Edition, Chapman and Hall, London, 1984. BH H + B 7. Budavari, S., Ed., The Merck Index, Twelth Edition, Merck & Co., Whitehouse Station, NJ, 1996.
    [Show full text]